# WASHINGTON UNIVERSITY INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCES

> **NIH NIH UL1** · WASHINGTON UNIVERSITY · 2021 · $67,736

## Abstract

PROJECT SUMMARY/ABSTRACT
The ACTIV public-private partnership has prioritized, designed, and harmonized five adaptive master
protocols for ACTIV clinical trials, and selected numerous NIH-supported networks to launch these clinical
trials to test prioritized therapeutic candidates. Master protocols allow coordinated and efficient evaluation of
multiple investigational agents as they become available, but within the same clinical trial structure, across
multiple study sites. Adaptive protocols swiftly weed out experimental drugs that do not demonstrate
effectiveness and identify those that do. Adaptive master protocols reduce administrative burden and cost,
provide a flexible framework to rapidly identify drugs that work, and rapidly move additional experimental
agents into the trial.
The ACTIV-1 master protocol is evaluating the safety and efficacy of at least three immune modulators (initially
infliximab, abatacept and cencicrivoroc when given as an add-on therapy to standard of care, which currently
includes remdesivir, The different treatments will be assessed with respect to illness severity, recovery speed,
mortality and hospital resource utilization. Dr. Powderly is the Principal investigator for ACTIV-1 and the
purpose of this supplement is to provide funding support for him and his Administrative Coordinator. In his
role, he will participate in regular conference calls with ACTIV and NCATS leadership as well as leading
weekly protocol team calls and regular calls with local PIs. He will review all safety events and other study
end-points and present regular reports to the DSMB. He will also coordinate the reporting of the results and
the writing of study manuscripts.

## Key facts

- **NIH application ID:** 10321102
- **Project number:** 3UL1TR002345-05S1
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** William G. Powderly
- **Activity code:** UL1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $67,736
- **Award type:** 3
- **Project period:** 2017-06-19 → 2022-03-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10321102

## Citation

> US National Institutes of Health, RePORTER application 10321102, WASHINGTON UNIVERSITY INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCES (3UL1TR002345-05S1). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10321102. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*